Stem cell–derived model offers insights on gene activity and addiction
Researchers at North Carolina State University have demonstrated that neuron-like cells derived from human stem cells can serve as a model for studying changes in the nervous system associated with addiction. The work sheds light on the effect of dopamine on gene activity in neurons, and offers a blueprint for related research moving forward.
“It is extremely difficult to study how addiction changes the brain at a cellular level in humans — nobody wants to experiment on somebody’s brain,” says , corresponding author of the study and an assistant professor of chemical and biomolecular engineering at NC State. “What we’ve done here demonstrates that we can gain a deep understanding of those cellular responses using neuronlike cells derived from human stem cells.”
At issue is how cells in our nervous system respond to drugs that are associated with substance abuse and addiction. Our bodies produce a neurotransmitter called dopamine. It’s associated with feelings, such as pleasure, that are related to motivation and reward. When neuronal cells in the brain’s “reward pathway” are exposed to dopamine, the cells activate a specific suite of genes, triggering the feelings of reward that can make people feel good. Many drugs — from alcohol and nicotine to opioids and cocaine — cause the body to produce higher levels of dopamine.
“In experiments using rodents, researchers have shown that when relevant neuronal cells are exposed to high levels of dopamine for an extended period of time, they become desensitized — meaning the cells’ gene activation is less pronounced in response to the dopamine,” Keung says. “This is called gene desensitization. However, until now, it hasn’t been possible to do an experimental study using human neuronal cells.”
“Our work here is the first experimental study to demonstrate gene desensitization in human neuronal cells, specifically in response to dopamine,” says , first author of the study and a Ph.D. student at NC State. “We don’t have to infer that it is happening in human cells; we can show that it is happening in human cells.”
In their , Tam and Keung exposed neuronlike cells derived from human stem cells to varying levels of dopamine for varying periods of time. The researchers found that when cells were exposed to high levels of dopamine for an extended period of time, the relevant “reward” genes became significantly less responsive. The work was published in the journal Cells.

“This is an interesting finding, but it’s also a proof of concept study,” Tam says. “We’ve demonstrated that gene desensitization to dopamine occurs in human cells, but there is still a lot we don’t know about the nature of the relationship between dopamine and gene desensitization.
“For example, could higher levels of dopamine cause desensitization at shorter time scales? Or could lower levels of dopamine cause desensitization at longer time scales? Are there threshold levels, or is there some sort of linear relationship? How might the presence of other neurotransmitters or bioactive chemicals affect these responses?”
“Those are good questions, which future research could address,” says Keung. “And we’ve demonstrated that these neuronlike cells derived from human stem cells are a good model for conducting that research.”
This article was republished with permission from North Carolina State University. Read the original.
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles

Teaching AI to listen
A computational medicine graduate student reflects on building natural language processing tools that extract meaning from messy clinical notes — transforming how we identify genetic risk while redefining what it means to listen in science.

Early lipid changes drive retinal degeneration in Zellweger spectrum disorder
Lipid profiling in a rare disease mouse model reveals metabolic shifts and inflammation in the retinal pigment epithelium — offering promising biomarker leads to combat blindness.

How sugars shape Marfan syndrome
Research from the University of Georgia shows that Marfan syndrome–associated fibrillin-1 mutations disrupt O glycosylation, revealing unexpected changes that may alter the protein's function in the extracellular matrix.

What’s in a diagnosis?
When Jessica Foglio’s son Ben was first diagnosed with cerebral palsy, the label didn’t feel right. Whole exome sequencing revealed a rare disorder called Salla disease. Now Jessica is building community and driving research for answers.

Peer through a window to the future of science
Aaron Hoskins of the University of Wisconsin–Madison and Sandra Gabelli of Merck, co-chairs of the 2026 ASBMB annual meeting, to be held March 7–10, explain how this gathering will inspire new ideas and drive progress in molecular life sciences.

Glow-based assay sheds light on disease-causing mutations
University of Michigan researchers create a way to screen protein structure changes caused by mutations that may lead to new rare disease therapeutics.